Invivyd WALTHAM, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) is pleased to announce the appointment of Ajay Royan to its Board of Directors. Mr. Royan is a venture ...

This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer .

WALTHAM, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) is pleased to announce the appointment of Ajay Royan to its Board of Directors. Mr. Royan is a venture capitalist ...

Invivyd has a fifty-two week low of $0.35 and a fifty-two week high of $4.74. Invivyd ( NASDAQ:IVVD – Get Free Report ) last issued its quarterly earnings data on Thursday, March 20th.

Invivyd has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500. Comparatively, Genocea Biosciences has a beta of 1.74, meaning that its share price is 74% more ...

WALTHAM, Mass. - Invivyd, Inc. (NASDAQ:IVVD), a biopharmaceutical company, announced today the addition of Ajay Royan to its Board of Directors. Royan, a venture capitalist known for investing in ...

WALTHAM, Mass. - Invivyd, Inc. (NASDAQ:IVVD), a biopharmaceutical company, announced today the addition of Ajay Royan to its Board of Directors. Royan, a venture capitalist known for investing in ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The latest analyst rating for Invivyd (NASDAQ:IVVD) was provided by HC Wainwright & Co., and Invivyd reiterated their buy rating. The last upgrade for Invivyd Inc happened on April 5, 2024 when ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...